Aflibercept versus Ranibizumab as a Second Line Therapy After Bevacizumab for Diabetic Macular Edema

Aflibercept versus Ranibizumab as a Second Line Therapy After Bevacizumab for Diabetic Macular Edema

Nasser G Alsaedi,1,2 Ruba M Alselaimy,3 Abdulaziz A Alshamrani,1 Muhammed AlAjmi,4 Rajiv Khandekar,1 Hassan Al-Dhibi,1 Abdulelah A Al-Abdullah1 1King Khaled Eye Specialist Hospital, Riyadh, Saudi Arabia; 2King Abdullah Medical City, Makkah, Saudi Arabia; 3College of Medicine, King Saud University, R...

Full description

Bibliographic Details
Main Authors:	Alsaedi NG, Alselaimy RM, Alshamrani AA, AlAjmi M, Khandekar R, Al-Dhibi H, Al-Abdullah AA
Format:	Article
Language:	English
Published:	Dove Medical Press 2021-07-01
Series:	Clinical Ophthalmology
Subjects:	aflibercept bevacizumab persistent dme ranibizumab vegf switch vascular endothelial growth factor
Online Access:	https://www.dovepress.com/aflibercept-versus-ranibizumab-as-a-second-line-therapy-after-bevacizu-peer-reviewed-fulltext-article-OPTH

Similar Items

Aflibercept monotherapy or bevacizumab first for diabetic macular edema
by: Avner Hostovsky, et al.
Published: (2024-01-01)

Intravitreal Aflibercept Therapy in Intravitreal Bevacizumab/Ranibizumab Treatment-resistant Exudative Age-related Macular Degeneration
by: Neslihan Sevimli, et al.
Published: (2023-09-01)

Results of switchback from ranibizumab to aflibercept in patients with exudative age-related macular degeneration
by: Koike N, et al.
Published: (2019-07-01)

The efficacy and ocular safety following aflibercept, conbercept, ranibizumab, bevacizumab, and laser for retinopathy of prematurity: a systematic review and meta-analysis
by: Jing Chen, et al.
Published: (2023-10-01)

Efficacy of Aflibercept versus Ranibizumab in the treatment of diabetic macular edema
by: Xiu-Xian Wang, et al.
Published: (2021-12-01)

Aflibercept versus Faricimab in the Treatment of Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema: A Review
by: Sławomir Liberski, et al.
Published: (2022-08-01)

Managing Diabetic Macular Edema in Clinical Practice: Systematic Review and Meta-Analysis of Current Strategies and Treatment Options
by: Veritti D, et al.
Published: (2021-01-01)

Efficacy of Aflibercept and Ranibizumab in the treatment of diabetic macular edema
by: Bing Wu, et al.
Published: (2023-08-01)

Evaluation of contrast sensitivity and other visual function outcomes in diabetic macular edema patients following treatment switch to aflibercept from ranibizumab
by: Nixon DR, et al.
Published: (2018-01-01)

Comparative study between ranibizumab and aflibercept in the management of macular edema caused by diabetes mellitus in age group more than 40 years
by: Abd El-Magid M Tag El-Din
Published: (2019-01-01)

Real-World Results of Switching Treatment from Ranibizumab to Aflibercept in Macular Oedema Secondary to Branch Retinal Vein Occlusion
by: Vasileios E. Konidaris, et al.
Published: (2018-10-01)

Patient adherence to therapy after switch to aflibercept from bevacizumab or ranibizumab for treatment-refractory neovascular age-related macular degeneration
by: Simon D Archambault, et al.
Published: (2024-01-01)

pH of anti-VEGF agents in the human vitreous: low impact of very different formulations
by: Bianka Sobolewska, et al.
Published: (2017-06-01)

Faricimab for Diabetic Macular Edema in Patients Refractory to Ranibizumab or Aflibercept
by: Hiromi Ohara, et al.
Published: (2023-06-01)

Clinical outcomes of switching to aflibercept using a pro re nata treatment regimen in patients with neovascular age-related macular degeneration who incompletely responded to ranibizumab
by: Flora Elwes, et al.
Published: (2018-01-01)

Comparative Study of Oct Angiographic Finding in Diabetic Macular Edema After Intravitreal Triamicinilone Acetonide Injection and Intravitreal Ranibizumab Injection
by: Mohamad Abu El-Maaty, et al.
Published: (2022-10-01)

Real-World Evidence in the Management of Diabetic Macular Edema with Intravitreal Anti-VEGFs in Asia: A Systematic Literature Review
by: Yuen YS, et al.
Published: (2022-10-01)

One-year results of switching to aflibercept for persistent diabetic macular edema resistant to bevacizumab
by: Mahmoud Alaa Abouhussein, et al.
Published: (2021-01-01)

Ranibizumab versus Aflibercept in Macular Edema Secondary to Retinal Vein Occlusion in Real Life: A Retrospective Case Control Study
by: Abdullah Özkaya, et al.
Published: (2017-05-01)

Comparison between the Effect of Aflibercept (Eylea) and Ranibizumab (Lucentis) on Intraocular Pressure after 3rd Injection in Treatment of Diabetic Macular Edema
by: Hossam El Deen Khalil, et al.
Published: (2022-07-01)

Ranibizumab versus aflibercept for macular edema secondary to nonischemic central retinal vein occlusion in young adult patients
by: Ahmed A Amer, et al.
Published: (2022-01-01)

A Real-Life Study: Intravitreal Aflibercept, Ranibizumab and Dexamethasone for Macular Edema Secondary to Branch Retinal Vein Occlusion
by: Alper Halil Bayat, et al.
Published: (2019-12-01)

Switching to Brolucizumab in Neovascular Age-Related Macular Degeneration Incompletely Responsive to Ranibizumab or Aflibercept: Real-Life 6 Month Outcomes
by: Christof Haensli, et al.
Published: (2021-06-01)

Comparative Safety of Bevacizumab, Ranibizumab, and Aflibercept for Treatment of Neovascular Age-Related Macular Degeneration (AMD): A Systematic Review and Network Meta-Analysis of Direct Comparative Studies
by: Anna A. Plyukhova, et al.
Published: (2020-05-01)

Effect of repeated intravitreal Ranibizumab and Aflibercept injections on the corneal nerves in patients with macular edema
by: Yuan-Yuan Qi, et al.
Published: (2023-05-01)

Ranibizumab or Aflibercept Monotherapies in Treatment-Naive Eyes with Diabetic Macular Edema: A Head-to-Head Comparison in Real-Life Experience
by: Mahmut Kaya, et al.
Published: (2023-02-01)

Comparison of 2-Year Outcomes between Intravitreal Ranibizumab and Intravitreal Aflibercept for Diabetic Macular Edema with “Treat-and-Extend” Regimen—Its Usefulness and Problems
by: Shinichiro Chujo, et al.
Published: (2020-09-01)

Evaluation of the Response to Ranibizumab Therapy following Bevacizumab Treatment Failure in Eyes with Diabetic Macular Edema
by: Joel Hanhart, et al.
Published: (2015-02-01)

Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab
by: Mohamed A. Hamid, et al.
Published: (2021-04-01)

Comparison of ranibizumab and bevacizumab in neovascular age-related macular degeneration
by: Huseyin Serdarogullari, et al.
Published: (2014-05-01)

Comparison of bevacizumab and ranibizumab in age-related macular degeneration:a systematic review and meta-analysis
by: Xiao-Yu Zhang, et al.
Published: (2014-04-01)

Comparison of aflibercept and bevacizumab in the treatment of type 1 retinopathy of prematurity
by: Hamid Riazi-esfahani, et al.
Published: (2021-10-01)

Intravitreal ranibizumab versus aflibercept versus bevacizumab for macular oedema due to central retinal vein occlusion: the LEAVO non-inferiority three-arm RCT
by: Philip Hykin, et al.
Published: (2021-06-01)

Uptake of Ranibizumab but Not Bevacizumab into Uveal Melanoma Cells Correlates with a Sustained Decline in VEGF-A Levels and Metastatic Activities
by: Aysegül Tura, et al.
Published: (2019-06-01)

Fc Receptor Inhibition Reduces Susceptibility to Oxidative Stress in Human RPE Cells Treated with Bevacizumab, but not Aflibercept
by: Mahdy Ranjbar, et al.
Published: (2016-02-01)

Effect of intravitreal aflibercept on recalcitrant diabetic macular edema
by: Kendra A. Klein, et al.
Published: (2017-04-01)

Efficacy of intravitreal injection of Aflibercept vs Ranibizumab in the treatment of diabetic retinopathy
by: Chang Huang, et al.
Published: (2021-05-01)

Monthly Alternating Injections of Aflibercept and Bevacizumab for Neovascular Age-Related Macular Degeneration
by: Junyeop Lee, et al.
Published: (2022-03-01)

Cost-effectiveness of dexamethasone compared with aflibercept in naïve diabetic macular edema
by: Paula Montes Rodríguez, et al.
Published: (2022-12-01)

Intravitreal aflibercept in neovascular age-related macular degeneration previously treated with ranibizumab
by: Rachel Hui Fen Lim, et al.
Published: (2017-03-01)